期刊文献+

心脏再同步化治疗对充血性心力衰竭患者内皮功能的影响 被引量:1

Effect of cardiac resynchronization therapy on vascular endothelial function in patients with congestive heart failure
原文传递
导出
摘要 目的:探讨心脏再同步化治疗(CRT)对充血性心力衰竭(心衰)患者内皮功能的影响。方法:扩张型心肌病并发心衰患者分为药物治疗组(10例)和CRT+药物治疗组(12例),分别在治疗前、治疗12周末,检测心脏超声、血管内皮功能、脑钠肽(BNP)。结果:与药物治疗组比较,CRT+药物治疗组明显增加患者的心脏输出量[(4.32±1.50)L/min∶(3.41±1.00)L/min,P<0.05]及肱动脉内径的变化率(FMD)[(1 718±123)%∶(976±118)%,P<0.05],FMD和心输出量呈正相关(r=0.6,P=0.003)。结论:CRT可以提高内皮细胞的功能,其机制可能是通过增加心输出量来实现的。 To explore the effect of cardiac resynchronization therapy (CRT) on vascular endothelial function in patients with congestive heart failure (CHF). Method:CHF patients with dilated cardiomyopathy were divided into optimal drug group (n = 10) and CRT+drug group (n = 12). Echocardiographic parameters, flow mediated diameter (FMD), brain natriuretic peptide (BNP) were evaluated before therapy and 12 weeks after therapy started. Result: Compared with drug group, cardiac output (E4.32 ± 1.50] L/min : [3.41 ± 1.00] L/min, P〈0.05) and FMD ([1718±123]% : [976±118]%, P〈0.05) were increased significantly in CRT+drug group. There was a positive correlation between FMD and cardiac output (r=0.6, P=0. 003). Conclusion: CRT could improve endothelial function by increasing cardiac output.
出处 《临床心血管病杂志》 CAS CSCD 北大核心 2012年第7期525-527,共3页 Journal of Clinical Cardiology
基金 浦东新区卫生系统重点学科建设基金资助项目(No:PWZXK-2010-05)
关键词 心力衰竭 充血性 心脏再同步化治疗 内皮功能 心输出量 heart failure, congestive cardiac resynchronization therapy endothelial function cardiac output
  • 相关文献

参考文献9

  • 1KATZ S D, HRYNIEWICZ K, HRILJAC I, et al. Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure [J]. Circulation, 2005,111:310- 314.
  • 2MEYER B, MORTL D, STRECKER K, et al. Flow- mediated vasodilation predicts outcome in patients with chronic heart failure: comparison with B-type natriuretic peptide[J]. J Am Coll Cardiol, 2005,46 : 1011 -- 1018.
  • 3AKYOL A, ALPER A T, CAKMAK N, et al. Longterm effects of cardiac resynchronization therapy on heart rate and heart rate variability[J].Tohoku J Exp Med, 2006,209:337- 346.
  • 4LINDE C, ABRAHAM W T, GOLD M R, el al. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomat ic patients with left ventricular dysfunction and previ ous heart failure symptoms[J]. J Am Coll Cardiol, 2008,52:1834-1843.
  • 5DAUBERT C, GOLD M R, ABRAHAM W T, et al. Prevention of disease progression by cardiac resyn- chronization therapy in palients with asymptomatic or mildly symptomatic left ventricular dysfunction: in- sights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial [J]. J Am Coll Cardiol, 2009,54 : 1837 - 1846.
  • 6CELERMAJER D S, SORENSEN K E, GOOCH V M, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis[J]. Lancet, 1992,340 : 1111- 11115.
  • 7BIAN K, DOURSOUT M F, MURAD F. Vascular system: role of nitric oxide in cardiovascular diseases [J]. J Clin Hypertens (Greenwich),2008,10:304- 310.
  • 8OBERLEITHNER H, CALL1ES C, KUSCHE-VI- HROG K, et al. Potassium softens vascular endothelium and increases nitric oxide release[J]. Proc Nail Acad Sci U S A,2009,106..2829-2834.
  • 9KATZ S D, KHAN T, ZEBAI.LOS G A, et al. Decreased activity of the I.-arginine-nitric oxide metabol- ic pathway in patients with congestive heart failure [J]. Circulation, 1999,99:2113- 2117.

同被引文献13

  • 1MEBAZAA A, NIEMINEN M S, PACKER M, et at. SURVIVE Investigators. Levosimendan vs dobu- tamine for patients with acute deeompensated heart failure: the SURVIVE Randomized Trial[J]. JAMA, 2007,297:1883--1891.
  • 2FLEVARI P, PARISSIS J T, LEFTHER1OTIS D, et al. Effect of levosimendan on ventricular arrhyth- mias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy[J]. Am J Car- diol, 2006,98 : 1641 -- 1645.
  • 3CHOGY, SONGJ K, PARKWJ, et al. Mechani- cal dyssynchrony assessed by tissue Doppler imaging is a powerful predictor of mortality in congestive heart failure with normal QRS duration[J]. J Am Coll Car- diol,2005,46:2237--2243.
  • 4FOSBOL E L, SEIBAEK M, BRENDORP B, et al. Danish Investigations and Arrhythmia on Dofetilide (Diamond) Study Group. Prognostic importance of change in QRS duration over time associated with left ventrieular dysfunction in patients with congestive heart failure., the D IAMOND study[J]. J Card Fail, 2008,14:850--855.
  • 5NG T M. Levosimendan, a new calcium-sensitizing inotropoe for heart failure [J]. Pharmacotherapy, 2004,24:1366-- 1384.
  • 6GHOGHIADE M, TEERLINK J R, MEBAZZA A. Pharmacology of new agents for acute heart failure syndromes[J]. Am J Cardiol, 2005,96 : 68-- 73.
  • 7MEBAZZA A, ERHARDT L. Levosimendan: a new daul-action drug in the treatment of acute heart failure [J]. Int J ClinPract,2003,57:410--416.
  • 8SONNTAG S, SUNDBERG S, LEHTONEN L A, et al. The calcium sensitizer Levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary agngioplasty in acute myocardi- al ischemia[J]. J Am Coil Cariol, 2004,43:2177 -- 2182.
  • 9AVGEROPOULOU C, ANDREADOU I, MARKANTO- NISKYROUDIS S, et al. The Ca2+ -sensitizer levosimen- dan improve osidative damage, BNP and pro-inflammatory cytokine level in patients with advanced decompensated heart failure in comparison to dobutamine[J]. Eur J Heart Fail, 2005,7 : 882 - 887.
  • 10OBERLEITHNER H, CALLIES C, KUSCHE-VI- HROG K, et al. Potassium softens vascular endothe- lium and increases nitric oxide release[J]. Proc Natl Acad Sci U S A,2009,106:2829--2834.

引证文献1

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部